Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 5 de 5
Filter
1.
J Neurooncol ; 148(3): 629-640, 2020 Jul.
Article in English | MEDLINE | ID: mdl-32602020

ABSTRACT

PURPOSE: Therapeutic intervention at glioblastoma (GBM) progression, as defined by current assessment criteria, is arguably too late as second-line therapies fail to extend survival. Still, most GBM trials target recurrent disease. We propose integration of a novel imaging biomarker to more confidently and promptly define progression and propose a critical timepoint for earlier intervention to extend therapeutic exposure. METHODS: A retrospective review of 609 GBM patients between 2006 and 2019 yielded 135 meeting resection, clinical, and imaging inclusion criteria. We qualitatively and quantitatively analyzed 2000+ sequential brain MRIs (initial diagnosis to first progression) for development of T2 FLAIR signal intensity (SI) within the resection cavity (RC) compared to the ventricles (V) for quantitative inter-image normalization. PFS and OS were evaluated using Kaplan-Meier curves stratified by SI. Specificity and sensitivity were determined using a 2 × 2 table and pathology confirmation at progression. Multivariate analysis evaluated SI effect on the hazard rate for death after adjusting for established prognostic covariates. Recursive partitioning determined successive quantifiers and cutoffs associated with outcomes. Neurological deficits correlated with SI. RESULTS: Seventy-five percent of patients developed SI on average 3.4 months before RANO-assessed progression with 84% sensitivity. SI-positivity portended neurological decline and significantly poorer outcomes for PFS (median, 10 vs. 15 months) and OS (median, 20 vs. 29 months) compared to SI-negative. RC/V ratio ≥ 4 was the most significant prognostic indicator of death. CONCLUSION: Implications of these data are far-reaching, potentially shifting paradigms for glioma treatment response assessment, altering timepoints for salvage therapeutic intervention, and reshaping glioma clinical trial design.


Subject(s)
Biomarkers, Tumor/analysis , Brain Neoplasms/pathology , Glioblastoma/pathology , Magnetic Resonance Imaging/methods , Neuroimaging/methods , Adult , Aged , Aged, 80 and over , Brain Neoplasms/surgery , Disease Progression , Female , Follow-Up Studies , Glioblastoma/surgery , Humans , Image Processing, Computer-Assisted , Male , Middle Aged , Prognosis , Retrospective Studies , Survival Rate
2.
Pharmacoepidemiol Drug Saf ; 29(6): 708-715, 2020 06.
Article in English | MEDLINE | ID: mdl-32173955

ABSTRACT

PURPOSE: Buprenorphine is an opioid partial agonist used to treat opioid use disorder. While several policy changes have attempted to increase buprenorphine availability, access remains well below optimal levels. This study characterized how buprenorphine utilization in the United States has changed over time and whether there are regional disparities in distribution of the medication. METHODS: The amount of buprenorphine distributed from 2007 to 2017 was obtained from the Drug Enforcement Administration's Automated Reports and Consolidated Ordering System. Data were expressed as the percent change and milligrams per person in each state. The formulations and cost for prescriptions covered by Medicaid (2008 to 2018) were also examined. RESULTS: Buprenorphine distributed to pharmacies increased about 7-fold (476.8 to 3179.9 kg) while the quantities distributed to hospitals grew 5-fold (18.6 to 97.6 kg) nationally from 2007 to 2017. Buprenorphine distribution per person was almost 20-fold higher in Vermont (40.4 mg/person) relative to South Dakota (2.1 mg/person). There was a strong association between the number of physicians authorized to prescribe buprenorphine and distribution per state (r[49] = +0.94, P < .0005). The buprenorphine/naloxone sublingual film (Suboxone) was the predominant formulation (92.6% of 0.31 million Medicaid prescriptions) in 2008 but accounted for less than three-fifth (57.3% of 6.56 million prescriptions) in 2018. CONCLUSIONS: Although buprenorphine availability has substantially increased over the last decade, distribution was very nonhomogeneous across the United States.


Subject(s)
Analgesics, Opioid/therapeutic use , Buprenorphine/therapeutic use , Drug Utilization/trends , Healthcare Disparities/trends , Opioid-Related Disorders/drug therapy , Practice Patterns, Physicians'/trends , Analgesics, Opioid/supply & distribution , Buprenorphine/supply & distribution , Buprenorphine, Naloxone Drug Combination/therapeutic use , Drug Compounding , Drug Prescriptions , Humans , Medicaid/trends , Opioid-Related Disorders/diagnosis , Opioid-Related Disorders/epidemiology , Time Factors , United States/epidemiology
3.
J Virol ; 90(17): 7991-8004, 2016 09 01.
Article in English | MEDLINE | ID: mdl-27356897

ABSTRACT

UNLABELLED: Influenza virus infections represent a significant socioeconomic and public health burden worldwide. Although ferrets are considered by many to be ideal for modeling human responses to influenza infection and vaccination, efforts to understand the cellular immune response have been severely hampered by a paucity of standardized procedures and reagents. In this study, we developed flow cytometric and T cell enzyme-linked immunosorbent spot (ELISpot) approaches to characterize the leukocyte composition and antigen-specific T cell response within key lymphoid tissues following influenza virus infection in ferrets. Through a newly designed and implemented set of serological reagents, we used multiparameter flow cytometry to directly quantify the frequency of CD4(+) and CD8(+) T cells, Ig(+) B cells, CD11b(+) myeloid-derived cells, and major histocompatibility complex (MHC) class II-positive antigen-presenting cells (APCs) both prior to and after intranasal infection with A/California/04/09 (H1N1). We found that the leukocyte composition was altered at 10 days postinfection, with notable gains in the frequency of T cells and myeloid cells within the draining lymph node. Furthermore, these studies revealed that the antigen specificity of influenza virus-reactive CD4 and CD8 T cells was very broad, with recognition of the viral HA, NA, M1, NS1, and NP proteins, and that total reactivity to influenza virus postinfection represented approximately 0.1% of the circulating peripheral blood mononuclear cells (PBMC). Finally, we observed distinct patterns of reactivity between individual animals, suggesting heterogeneity at the MHC locus in ferrets within commercial populations, a finding of considerable interest in efforts to move the ferret model forward for influenza vaccine and challenge studies. IMPORTANCE: Ferrets are an ideal animal model to study transmission, diseases, and vaccine efficacies of respiratory viruses because of their close anatomical and physiological resemblances to humans. However, a lack of reagents has limited our understanding of the cell-mediated immune response following infection and vaccination. In this study, we used cross-reactive and ferret-specific antibodies to study the leukocyte composition and antigen-specific CD4 and CD8 T cell responses following influenza A/California/04/09 (H1N1) virus infection. These studies revealed strikingly distinct patterns of reactivity between CD4 and CD8 T cells, which were overlaid with differences in protein-specific responses between individual animals. Our results provide a first, in-depth look at the T cell repertoire in response to influenza infection and suggest that there is considerable heterogeneity at the MHC locus, which is akin to that in humans and an area of intense research interest.


Subject(s)
Cytokines/analysis , Immunity, Cellular , Influenza A Virus, H1N1 Subtype/immunology , Orthomyxoviridae Infections/immunology , Animals , Antigen-Presenting Cells/immunology , B-Lymphocytes/immunology , Enzyme-Linked Immunospot Assay , Female , Ferrets , Flow Cytometry , Lymph Nodes/immunology , Myeloid Cells/immunology , T-Lymphocytes/immunology
4.
Arch Environ Contam Toxicol ; 64(3): 504-13, 2013 Apr.
Article in English | MEDLINE | ID: mdl-23229196

ABSTRACT

Selenium (Se) is an essential micronutrient with a narrow therapeutic concentration range. The relative toxicity of Se increases as it is biotransformed into organic compounds, primarily selenomethionine (SeMet), within the aquatic food chain. Effects of aquatic Se contamination are well quantified for many freshwater fish and aquatic bird species, but impacts on amphibians are not well known. This study investigated the responses of larval Cope's gray tree frogs (Hyla chrysoscelis) fed a diet enriched with one of two concentrations of SeMet (50.1 and 489.9 µg Se g(-1) dw [low and high groups, respectively]) by way of a food-limited (ration) or ad libitum (ad lib) feeding regimen. The high dose caused 100 % mortality during the larval period independent of resource provision levels. Regardless of feeding regimen, the low dose decreased larval survival and successful metamorphosis relative to control treatments. The low dose also induced rear limb deformities in ≤73 % of individuals initiating metamorphosis. Providing low-dose food by way of a rationed feeding regimen decreased observed toxicity, likely because of decreased dietary exposure to SeMet relative to the low ad lib treatment. Individuals from the low ration treatment had decreased wet mass at initiation and completion of metamorphic climax (Gosner stages 42 through 46) compared with those from the control ad lib treatment, indicating that resource limitation combined with Se exposure might negatively affect energy stores after metamorphosis. However, lipid content analyses of recently metamorphosed individuals did not reveal any influence of treatment or resource provision on energy stored as lipids. The mean tissue Se concentration of individuals that received the low dose and completed metamorphosis was significantly greater than that of control ad lib or ration individuals at the same developmental stage. This study demonstrates that larval exposure to dietary SeMet can decrease growth and survival and induce deformities in a developing amphibian. Furthermore, retention of Se body burdens through metamorphosis suggests that surviving individuals can transport Se accumulated from contaminated aquatic environments into terrestrial food webs.


Subject(s)
Body Weight/drug effects , Limb Deformities, Congenital/chemically induced , Metamorphosis, Biological/drug effects , Selenomethionine/toxicity , Administration, Oral , Animals , Anura , Dose-Response Relationship, Drug , Larva/drug effects , Larva/growth & development , Lipid Metabolism/drug effects , Selenomethionine/pharmacokinetics , Survival Analysis
SELECTION OF CITATIONS
SEARCH DETAIL